bims-toxgon Biomed News
on Toxoplasma gondii metabolism
Issue of 2026–11–22
six papers selected by
Lakesh Kumar, BITS Pilani



  1. EMBO Rep. 2026 Nov 20.
      Apicomplexan parasites rely on a specialized apical cytoskeleton to generate the forces required for motility and host-cell invasion. At its core lies the conoid, composed of spiraling tubulin fibers capped by three preconoidal rings (PCRs), which anchor the actin nucleator Formin 1 and contribute to force transmission at the parasite apex. Here, we refine the molecular organization and function of the PCRs in Toxoplasma gondii. We show that PCR composition and stability change during parasite maturation, with a subset of PCR proteins, Pcr2 and Pcr3, adopting a characteristic half-ring organization. We identify MyoL, a divergent pseudomyosin, as a previously unrecognized PCR component. MyoL is essential for efficient gliding and invasion, and its depletion partially detaches the PCRs from the conoid. Structure-function analysis further identifies the MyoL neck and tail as critical for PCR localization and activity. Together, our findings provide new insight into the organization of this conserved apicomplexan complex and reveal an unexpected architectural role for a pseudomyosin in maintaining the PCR-conoid interface.
    DOI:  https://doi.org/10.1038/s44319-026-00995-y
  2. mBio. 2026 Nov 16. e0208026
      The apicomplexan guanylate cyclase (GC) complex acts as a signaling hub linking environmental sensing to lytic growth via production of cyclic guanosine monophosphate (cGMP). In Toxoplasma gondii, at least three accessory proteins (CDC50.1, UGO, and SLF) form a complex with GC to regulate its trafficking and activity. To further resolve the assembly and composition of the GC complex in T. gondii, we screened for novel interactors of GC using proximity-dependent biotin identification (BioID). In addition to all known GC complex members, we identified a highly enriched hypothetical protein (TGGT1_294940) that is restricted to the Sarcocystidae family of tissue-cyst-forming apicomplexans. 294940 possesses an N-terminal signal peptide followed by a single transmembrane motif, an architecture reminiscent of resident endoplasmic reticulum (ER) type I membrane proteins. Super-resolution imaging and biochemical fractionation established 294940 as a resident ER membrane protein, distinguishing it from the mature GC complex, which localizes to the apical plasma membrane. Conditional depletion of 294940 delayed replication and substantially impaired egress in tachyzoites, ablating lytic growth. Analysis of the 294940 interactome by co-immunoprecipitation revealed GC and CDC50.1 as its top two interactors, while UGO and SLF were unexpectedly absent, suggesting that 294940 regulates an initial step of GC complex assembly in the ER. Loss of 294940 caused rapid degradation of the GC chaperone CDC50.1, preventing GC exit from the ER and subsequent apical trafficking. Collectively, these data support a model whereby 294940 drives nascent CDC50.1-GC complex assembly in the ER for trafficking to the apical plasma membrane. Thus, we propose naming 294940 CDC50.1-Guanylate Cyclase Assembly Factor 1 (CGAF1).
    IMPORTANCE: Cyclic GMP signaling is essential for motility, egress, and host cell invasion in apicomplexan parasites, yet how the guanylate cyclase (GC) signaling complex is assembled and delivered to the parasite surface remains poorly understood. Our study identifies CGAF1 as a previously uncharacterized, ER-resident membrane protein required for GC complex biogenesis. We show that CGAF1 acts at an early assembly step, enabling GC to pair with its chaperone CDC50.1 in the ER; without CGAF1, CDC50.1 is degraded, and GC fails to traffic to the apical plasma membrane, resulting in defective cGMP-dependent egress. These findings identify the first dedicated assembly factor for a CDC50-P4-ATPase or CDC50-GC complex in any organism and reveal that Sarcocystidae parasites have evolved a unique strategy, or quality checkpoint, for assembling these complexes. Understanding how apicomplexans build and deploy their GC signaling machinery offers new insight into the molecular basis of parasite egress and may point to lineage-specific vulnerabilities for therapeutic intervention.
    Keywords:  BioID; CDC50; P4-ATPase; Toxoplasma gondii; apicomplexan parasites; cyclic GMP; egress; guanylyl cyclases; protein trafficking
    DOI:  https://doi.org/10.1128/mbio.02080-26
  3. bioRxiv. 2026 Nov 03. pii: 2026.10.10.758213. [Epub ahead of print]
      Histone deacetylase 6 (HDAC6) plays an essential role in the regulation of post-translational lysine acetylation. Myriad biological processes depend on the precise regulation of lysine acetylation-deacetylation cycles, and their dysregulation is linked to human pathologies such as cancer and neurodegeneration. Broad-specificity HDAC inhibitors are efficacious in treating disease, but the inhibitors currently approved for clinical use often cause deleterious side effects due to inhibition of multiple HDAC isozymes as well as other zinc enzymes. Cyclic peptides comprise novel platforms that, in principle, can be tailored for affinity and selectivity. A key advantage of cyclic peptide design is the ability to incorporate both canonical and noncanonical amino acids. As part of our program focusing on cyclic peptide HDAC inhibitors, we now report the 1.9-Å resolution crystal structure of HDAC6 CD2 complexed with macrocyclic nonapeptide 1 . The structure reveals zinc coordination by a noncanonical thiolate-containing amino acid, plus direct and water-mediated enzyme-inhibitor hydrogen bonds that contribute to nanomolar inhibitory potency. Structural comparisons with previously reported HDAC6 CD2 complexes with tetrapeptide and octapeptide macrocycles reveal similar networks of direct and water-mediated interactions. Given the surge of interest in cyclic peptide inhibitors, fueled in part by advances in computational design approaches, the crystal structure of the HDAC6 CD2- 1 complex sets an important foundation for further development of macrocyclic peptide inhibitors.
    For Table of Contents Use Only:
    DOI:  https://doi.org/10.64898/2026.10.10.758213
  4. bioRxiv. 2026 Nov 14. pii: 2026.11.13.766473. [Epub ahead of print]
      Toxoplasma gondii , a pathogen with a global burden impacting millions, has the capability to interconvert between the actively replicating tachyzoite form into a semi- dormant bradyzoite for, complicating treatment. Here, we utilized an advanced high- throughput screen (HTS) to identify repurposing candidates from the ReFRAME library, which consolidates 14,095 molecules from three major databases, including FDA- approved and late-stage clinical leads. To facilitate screening, the permissive cyst- forming Tg 68 strain was genetically engineered to express nano luciferase under the pBAG1 promoter to track bradyzoite growth, and firefly luciferase under the pTub1 promoter to monitor tachyzoite growth. HTS in 384-well format identified 160 compounds that exhibited > 80% inhibition at 10 µM of both tachyzoites and bradyzoites. By cross-referencing against a publicly available HEK293T cytotoxicity dataset, we filtered out 61 compounds based on half-maximal cytotoxicity (CC 50 ) less < 5 µM, leaving 99 for further evaluation. From this set, 15 top hits were identified based on potency and the selective index (CC 50 :EC 50 ; SI > 20) against HepG2. The top hits were profiled using in vitro growth assays for tachyzoites, bradyzoites, and ex vivo liberated and intact cysts. Marizomib, monensin, narasin, and LY-2090314 showed the strongest inhibition following 24 h treatment of intact cysts. When tested in combination with clinical compounds atovaquone and pyrimethamine, the top hits were predominantly additive. Additionally, they were evaluated for their potential for developing resistance using a minimum inoculum of resistance (MIR) assay. Six of nine compounds tested in MIR assays yielded no detectable parasites over 30 days. In contrast, LY-2090314-resistant populations exhibited 26-29-fold resistance and carried a TgGSK3 L53V mutation, identifying a candidate resistance determinant. Collectively, our findings identify compounds with activity against tachyzoites and bradyzoites and with low propensity for resistance, as starting points for mechanistic investigation and further evaluation of in vivo efficacy and host-toxicity liabilities.
    DOI:  https://doi.org/10.64898/2026.11.13.766473
  5. Cancer Med. 2026 Nov;pii: e72520. [Epub ahead of print]15(11):
      Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) is a multifunctional protein that participates in cancer metabolism, apoptosis, DNA repair, angiogenesis, and immune regulation beyond its canonical glycolytic role. However, how distinct post-translational modifications (PTMs) coordinate GAPDH functional transitions and determine its diverse biological roles in cancer remains incompletely understood. In this review, we summarize current advances in GAPDH PTMs, including methylation, phosphorylation, acetylation, ubiquitination, S-nitrosylation, serotonylation, crotonylation, lactylation, and succinylation, with emphasis on modification sites, regulatory enzymes, cellular contexts, and functional consequences. We propose a PTM-driven molecular switching model in which different cellular stimuli induce specific GAPDH modifications to regulate its enzymatic activity, subcellular localization, and protein interactions. Representative mechanisms include Src-mediated Tyr41 phosphorylation promoting DNA repair and 5-fluorouracil resistance in colorectal cancer, K254 and K160 acetylation regulating glycolytic activity and apoptosis through distinct cellular contexts, Parkin-mediated ubiquitination controlling mitophagy and metabolic reprogramming, and Gln262 serotonylation enhancing CD8+ T-cell glycolytic function and antitumor immunity. We further discuss the crosstalk among GAPDH PTMs and critically evaluate the current evidence, limitations, and therapeutic implications of GAPDH modification-based regulation. Although GAPDH PTMs represent promising targets for cancer intervention, current evidence is mainly derived from cellular and preclinical models, and PTM-specific therapeutic strategies remain limited. Further studies are required to clarify the cancer-specific functions and clinical relevance of GAPDH PTM networks.
    Keywords:  GAPDH; glycolysis; post‐translational modifications; tumor
    DOI:  https://doi.org/10.1002/cam4.72520
  6. Genomics Proteomics Bioinformatics. 2026 Nov 14. pii: qzag112. [Epub ahead of print]
      Histone deacetylase 2 (HDAC2) may contribute to epigenetic dysregulation in esophageal squamous cell carcinoma (ESCC) by silencing tumor suppressor genes, yet isoform-specific therapeutic targeting remains underexplored. Here, we show that romidepsin, an FDA-approved class I HDAC inhibitor, preferentially inhibits HDAC2-associated deacetylation in ESCC cells. We identified romidepsin as a potent inhibitor of ESCC cell viability, through phenotypic screening of 773 epigenetic compounds across differentiation-stage-defined ESCC models. Multi-omics analyses (SILAC proteomics, CUT&Tag chromatin mapping, and RNA-seq) further revealed histone H3K14ac enrichment at promoters of p53 pathway targets, including CDKN1A/p21, which exhibited transcriptional reactivation. Similar to HDAC2 knockout, romidepsin suppressed ESCC proliferation, migration, and clonogenicity. Mechanistically, HDAC2 inhibition reverses epigenetic silencing of p21 and restores tumor-suppressive chromatin states. Together, these results identify the HDAC2-H3K14ac axis as a therapeutic vulnerability in ESCC and provide preclinical support for romidepsin-based epigenetic intervention.
    Keywords:  Cell proliferation; Esophageal squamous cell carcinoma; HDAC2; Histone H3K14ac; Proteomics
    DOI:  https://doi.org/10.1093/gpbjnl/qzag112